Biochemistry, Genetics and Molecular Biology
Protein Kinases
100%
Kinome
100%
Hsp90
100%
Herpesviridae
100%
Adenosine Triphosphate
100%
Estrogen Receptor
100%
DNA Sequence
100%
Competitive Inhibition
100%
Next Generation Sequencing
100%
Hsp90 Inhibitor
66%
Interactome
66%
Epidermal Growth Factor Receptor
66%
Autophagy
66%
Drug Resistance
66%
Mutagenesis
33%
Proteomics
33%
Sensitive Detection
33%
Downregulation
33%
Phosphotransferase
33%
Kinase
33%
Epstein Barr Virus
33%
Mouse
33%
Mitogen-Activated Protein Kinase
27%
Cancer Cell
9%
RNA Sequence
9%
Reprogramming
9%
Induced Resistance
9%
MEK Inhibitor
9%
Exome Sequencing
9%
Insulin Receptor
9%
FGF3
9%
Fulvestrant
9%
Cross Resistance
9%
Medicine and Dentistry
Targeted Therapy
100%
Adenosine Kinase
100%
Nucleoside Analogue
100%
Cancer
100%
Plasma Cell
100%
Primary Effusion Lymphoma
100%
Estrogen Receptor
100%
Metastatic Breast Cancer
100%
Multiple Myeloma
75%
Neoplasm
34%
In Vitro
34%
RNA Sequence
34%
Mitogen-Activated Protein Kinase
27%
S Phase
25%
Cell Death
25%
Immunohistochemistry
25%
Multiple Myeloma Cell Line
25%
Malignant Neoplasm
25%
DNA Damage
25%
Adenosine Triphosphate
25%
Lymphoma Cell Line
25%
Biological Marker
25%
B Cell
25%
Plasmablastic Lymphoma
25%
T-Cell Lymphoma
25%
Lymphoma
25%
Leukemia Cell
25%
Breast Cancer
18%
Biopsy
18%
Fibroblast Growth Factor Receptor 2
18%
Induced Resistance
9%
MEK Inhibitor
9%
Cross Resistance
9%
Insulin Receptor
9%
Exome Sequencing
9%
Fibroblast Growth Factor Receptor 1
9%
Fulvestrant
9%
Fibroblast Growth Factor 3
9%
Cancer Cell
9%
Resistant Cell Line
9%
Palbociclib
9%
Combination Drug
9%
Keyphrases
Inhibitor Resistance
100%
Protein Kinase
100%
ATP-competitive Inhibitors
100%
PU-H71
100%
Kinome
100%
Resistance mutations
66%
Human Epidermal Growth Factor Receptor 2 (HER2)
66%
Drug Resistance
66%
CSNK2A1
33%
Scanned Data
33%
Resistant mutants
33%
ERK2
33%
MEK1
33%
TANK-binding Kinase 1 (TBK1)
33%
Drug Discovery
33%
Cyclin-dependent Kinase 6 (CDK6)
33%
Kinase Drugs
33%
Activation Sites
33%
Clinically Significant
33%
Disease Development
33%
Kinase Activity
33%
Deep mutational Scanning
33%
Cyclin-dependent Kinase 4 (CDK4)
33%
Mutagenesis
33%
CCNE2
28%
Resistome Analysis
25%
Purine Scaffold
16%
NGS Library
11%
Fulvestrant Resistance
10%
Candidate Resistance Genes
10%
CDK6 Inhibitors
9%
CDK4 Inhibitors
9%
Inference Step
5%
Interpretation of Research Results
5%